Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Production of Pharmaceuticals01:30

Production of Pharmaceuticals

81
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
81
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

268
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
268
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

251
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
251
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

229
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
229
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

227
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
227
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

176
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
176

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rabbit medicine.

International journal of pharmaceutical compounding·2013
Same author

A treatment of stomatitis and treatment in cats.

International journal of pharmaceutical compounding·2013
Same author

Goliath: case report on a canine case of epilepsy.

International journal of pharmaceutical compounding·2013
Same journal

Compounding and Stability Study of Dipyridamole and Clopidogrel Pediatric Oral Suspensions.

International journal of pharmaceutical compounding·2026
Same journal

Nanoemulsion Reformulation of Nitrosylcobalamin (NO-Cbl) Enhances Solubility, Stability, and Anti-Tumor Potency.

International journal of pharmaceutical compounding·2026
Same journal

Chemical and Microbiological Stability Supporting Extended BUDs in Pentravan® Based Transdermal Preparations.

International journal of pharmaceutical compounding·2026
Same journal

Stability Evaluation of Compounded Benzocaine, Lidocaine, and Tetracaine in VersaPro™ Cream Base.

International journal of pharmaceutical compounding·2026
Same journal

Formulation and In-Vitro Characterization of Gastroretentive Effervescent Floating Tablets of Meloxicam.

International journal of pharmaceutical compounding·2026
Same journal

Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities.

International journal of pharmaceutical compounding·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs
08:40

Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs

Published on: April 19, 2024

4.1K

The future of veterinary compounding

Dinah G Jordan1

  • 1College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762, USA. MintJulep@cvm.msstate.edu

International Journal of Pharmaceutical Compounding
|January 14, 2015
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

8.1K
Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs
04:05

Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs

Published on: July 5, 2024

837

Related Experiment Videos

Last Updated: Apr 18, 2026

Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs
08:40

Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs

Published on: April 19, 2024

4.1K
Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

8.1K
Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs
04:05

Surgical Model for Single-Staged Tissue-Engineered Urothelial Tubes in Minipigs

Published on: July 5, 2024

837